Sandoz introduces CellCept generic

PRINCETON, N.J. The generics arm of Novartis has introduced its version of a drug used to prevent rejection of transplanted organs.

Sandoz announced Friday that it had launched mycophenolate mofetil tablets in the 500-mg strength and capsules in the 250-mg strength. The drug is a generic version of Roche’s CellCept, which prevents the immune system from rejecting transplated hearts, livers and kidneys.

CellCept and its generic equivalents had sales of $1.024 billion for the 12 months ending in February, according to IMS Health.